Literature DB >> 6511898

Management of the resistant myelodysplastic or arthrogrypotic clubfoot with the Verebelyi-Ogston procedure.

T D Spires, R H Gross, W Low, W Barringer.   

Abstract

The Verebelyi-Ogston (V-O) procedure, consisting of subchrondral excision of the talus and cuboid, was used for the treatment of 13 resistant clubfeet secondary to myelomeningocele or arthrogryposis. Nine feet were initially satisfactory, but the condition recurred in both feet of one patient after bracing was discontinued 3 years postoperatively. Three feet were graded as satisfactory after a second V-O procedure, and one after a third. The procedure must be monitored by intraoperative fluoroscopy or radiography, and followed by orthotic support. Despite the theoretical long-term disadvantage of incongruent joint surfaces, we consider the V-O procedure to be a good method for the treatment of this subset of rigid neuropathic clubfeet.

Entities:  

Mesh:

Year:  1984        PMID: 6511898     DOI: 10.1097/01241398-198411000-00010

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  4 in total

1.  Re-do clubfoot: surgical approach and long-term results.

Authors:  W B Lehman; D Atar; A D Grant; A M Strongwater
Journal:  Bull N Y Acad Med       Date:  1990 Nov-Dec

2.  Tarsal decancellation in the residual resistant arthrogrypotic clubfoot.

Authors:  Hany N Iskandar; Sherif N G Bishay; Hatem Abdel-Rahman Sharaf-El-Deen; Mohsen Mohammad El-Sayed
Journal:  Ann R Coll Surg Engl       Date:  2010-11-04       Impact factor: 1.891

3.  Correction of arthrogrypotic clubfoot with a modified Ponseti technique.

Authors:  Harold J P van Bosse; Salih Marangoz; Wallace B Lehman; Debra A Sala
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

4.  Short-term experience with Ponseti casting and the Achilles tenotomy method for clubfeet treatment in arthrogryposis multiplex congenita.

Authors:  Bartholomew Kowalczyk; Tadeusz Lejman
Journal:  J Child Orthop       Date:  2008-08-22       Impact factor: 1.548

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.